The fixed combination of halobetasol and tazarotene topicals significantly reduced the severity of localized disease with a favorable safety profile, shows a study published in the Journal of the American Academy of Dermatology.
Therapeutic Considerations for Psoriasis
Dermatologists need to be aware of margin of error and related issues that can affect the results of biosimilar clinical trials, a study shows.
Switching from adalimumab to etanercept or vice versa after interruption can improve treatment response, data presented in London suggests.
Phase three trials of the selective IL-23 blocker risankizumab are replicating the promising results achieved by phase two trials for psoriasis, researchers report in London.
Secukinumab has been shown to be effective for the treatment of moderate-to-severe plaque psoriasis in hard-to-treat patients who failed anti-TNFa treatment, researchers report in London.
Adding caffeine to topical skin treatments would be a simple way to reduce inflammation in patients with atopic dermatitis and psoriasis, suggests a review presented at the Psoriasis: From Gene to Clinic International Congress, which took place in London this week.
Patients with psoriasis are more likely than the general population to receive a diagnosis of malignant lymphoma. Why? Cutaneous T-cell lymphoma is misdiagnosed as psoriasis and can also be mistaken for atopic dermatitis due to similarities in the skin manifestation.
One dermatologist describes his considerations for choosing a biologic to treat a patient with moderate-to-severe psoriasis, baseline assessments, and follow-up approach.
Exciting research is likely to change treatment for children. Dr. Eichenfield discusses advancements in treating this population.
A recent study provides more evidence that patients with psoriasis–even mild cases–face a higher risk of major depression, a finding that could lead dermatologists to alert patients with the condition and even screen them for mental health issues.